The Small Print
From semi-conductors to sight-saving therapies: introducing PRINT Technology
Phoebe Harkin |
The need to produce smaller, more sophisticated drug or drug-delivery particles presents a challenge to pharmaceutical manufacturers. So, how do you guarantee high batch reproducibility and dose uniformity on a commercial scale? Simple – you look to the industries who do it best. Or at least, that’s what Aerie Pharmaceuticals did when they acquired the rights from Envisia Therapeutics, Inc. to use Particle Replication in Non-wetting Templates – also known as PRINT® – technology in October 2017.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.